通过p38 MAPK通路,MKRN2增强了肝细胞癌的扩散
Xiaojing Chen1, Zihan Yan2, Xinrui Du2
1Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China.
马科林-2 (MKRN2) 通过通过p38 MAPK通路推动细胞循环进展,促进肝细胞癌 (HCC) 的生长. MKRN2上调与HCC预后不佳相关,这表明它是潜在的治疗标.
科学领域:
- 分子瘤学分子瘤学
- 细胞生物学 细胞生物学
- 癌症的发病因子 癌症的发病因子
背景情况:
- 肝细胞癌 (HCC) 病原体需要阐明,以便开发有针对性的治疗方法.
- 马科林-2 (MKRN2),一种E3泛素结合酶,与各种癌症有关,但其在HCC中的作用尚不清楚.
- 了解MKRN2在HCC中的功能对于确定新的治疗策略至关重要.
研究的目的:
- 研究肝细胞癌 (HCC) 中马科林-2 (MKRN2) 的生物学作用和分子机制.
- 确定MKRN2表达和HCC患者预后之间的相关性.
- 探索MKRN2作为HCC治疗点的潜力.
主要方法:
- 定量实时PCR和免疫组织化学评估MKRN2表达.
- 细胞增殖试验 (CCK-8,殖民地形成,EDU) 来评估HCC细胞生长.
- RNA测序 (RNA-seq),流细胞测量,西式涂抹和异种移植小鼠模型以阐明分子机制.
主要成果:
- 在HCC组织中,MKRN2表达显著上调,并与患者预后不佳有关.
- MKRN2 枯竭减弱了 HCC 细胞增殖,并在 G1/S 过渡时诱导细胞周期停止.
- 通过激活p38 MAPK通路,MKRN2促进HCC的进展,从而导致c-Myc的激活和增强的扩散.
结论:
- MKRN2在促进HCC细胞周期进展和增殖方面发挥着至关重要的作用.
- p38 MAPK信号通路是MKRN2在HCC中的致癌功能的关键调解者.
- MKRN2代表了肝细胞癌的一个有前途的治疗点.
更多相关视频
07:47Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
Published on: August 31, 2022
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
相关概念视频
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
